Skip to main content

Table 2 Therapeutic effects, adverse events and regimen changes in the four patient groups

From: Impact of renal function-based anti-tuberculosis drug dosage adjustment on efficacy and safety outcomes in pulmonary tuberculosis complicated with chronic kidney disease

  Total Non-CKD CKD group Subtotal of CKD groups P value*
Mild CKD Moderate CKD Severe CKD
n = 241 n = 87 n = 93 n = 43 n = 18 n = 154
Therapeutic effects
 In-hospital TB-related death 14 (5.8%) 3 (3.4%) 5 (5.4%) 5 (11.6%) 1 (5.6%) 11 (7.1%) 0.310
 Sputum culture conversion at 2 months 174 (78.0%) 67 (77.9%) 66 (76.7%) 28 (77.8%) 13 (86.7%) 107 (78.1%) 0.864
Any adverse events 60 (24.9%) 18 (20.7%) 19 (20.4%) 15 (34.9%) 8 (44.4%) 42 (27.3%) 0.051
No adverse event 181 (75.1%) 69 (79.3%) 74 (79.6%) 28 (65.1%) 10 (55.6%) 112 (72.7%)
Drug-induced hepatitis 28 (11.6%) 6 (6.9%) 12 (12.9%) 8 (18.6%) 2 (11.1%) 22 (14.3%) 0.252
Cutaneous reaction 19 (7.9%) 8 (9.2%) 6 (6.5%) 3 (7.0%) 2 (11.1%) 11 (7.1%) 0.855
Drug-induced nephropathy 7 (2.9%) 0 (0%) 0 (0%) 5 (11.6%) 2 (11.1%) 7 (4.5%) N/A
Gastrointestinal disorder 6 (2.5%) 1 (1.1%) 2 (2.2%) 1 (2.3%) 2 (11.1%) 5 (3.2%) N/A
Gout attack 5 (2.1%) 4 (4.6%) 0 (0%) 0 (0%) 1 (5.6%) 1 (0.6%) N/A
Haematotoxicity 3 (1.2%) 0 (0%) 2 (2.2%) 0 (0%) 1 (5.6%) 3 (1.9%) N/A
Peripheral neuropathy 1 (0.4%) 1 (1.1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) N/A
Anaphylaxis 1 (0.4%) 0 (0%) 0 (0%) 1 (2.3%) 0 (0%) 1 (0.6%) N/A
Regimen change 28 (11.6%) 3 (3.4%) 10 (10.8%) 9 (20.9%) 6 (33.3%) 25 (16.2%) < 0.001
  1. There was some overlap
  2. *Chi-square test was used to compare for each parameter
  3. N/A, chi-square test was not applicable because of insufficient expected values in some cells
  4. §The number of patients alive at 2 months was 223 (86 patients in the non-CKD group, 86 in the mild CKD group, 36 in the moderate CKD group and 15 in the severe CKD group)
  5. CKD chronic kidney disease